Oncogenic proteins MMP1 and BMP2, together with LBH, which suppresses tumor progression, have been found to act as downstream effectors of MIR31HG. To target MIR31HG is likely to have significant therapeutic efficacy due to the resulting concomitant modulation of multiple downstream effector genes. This evidence concerns the gene MMP1 and neoplasm.